Novartis, Mylan Settle Feud Over Generic Vivelle-Dot

Law360, New York (November 21, 2011, 7:09 PM EST) -- Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be manufactured, Mylan announced Monday.

Under the settlement, Novartis will drop its lawsuits in New York and Vermont against Mylan and Mylan will receive a patent license to begin selling its generic version of Vivelle-Dot beginning in December 2013, subject to the approval by the U.S. Department of Justice and the Federal Trade Commission, according to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.